Center-Authored Papers

Filters: Author is Borthakur, Gautam  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
X-Linked Inhibitor of Apoptosis Protein
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW et al..  2009.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4741-6. Abstract
Vidarabine
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.  2008.  Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.. Cancer. 113(11):3181-5. Abstract
Vegetables
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Treatment Outcome
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW et al..  2009.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4741-6. Abstract
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.  2008.  Relapse and death during first remission in acute myeloid leukemia.. Haematologica. 93(4):633-4.
Time Factors
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH.  2011.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33):4417-24. Abstract
Survival Analysis
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.  2008.  Relapse and death during first remission in acute myeloid leukemia.. Haematologica. 93(4):633-4.
Specimen Processing Core Facility
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G.  2014.  A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia. 14(5):395-400.e1. Abstract
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia T, Ruvolo P, Feliu JB et al..  2014.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(8):2226-35. Abstract
Shared Resources
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH.  2011.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33):4417-24. Abstract
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
RNA, Messenger
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW et al..  2009.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4741-6. Abstract
RISK
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.  2008.  Relapse and death during first remission in acute myeloid leukemia.. Haematologica. 93(4):633-4.
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH.  2011.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33):4417-24. Abstract
Reverse Transcriptase Polymerase Chain Reaction
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW et al..  2009.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4741-6. Abstract
Research Trials Office Core Facility - Biostatistics Service
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia T, Ruvolo P, Feliu JB et al..  2014.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(8):2226-35. Abstract
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G.  2014.  A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia. 14(5):395-400.e1. Abstract
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH.  2011.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33):4417-24. Abstract
Remission Induction
Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E.  2008.  Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.. Leukemia research. 32(10):1505-9. Abstract
Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E.  2008.  Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.. Haematologica. 93(8):1263-5.